Abstract:Diabetes and cardiovascular diseases(CVD) are the risk factors for each other, which seriously affect the health and quality of life of patients. Sodium glucose co-transporter 2 (SGLT2) inhibitor is a new oral hypoglycemic drug listed in recent years and may have a protective effect on CVD demonstrated by many studies. The protective mechanism is mainly built-up in decreasing the traditional risk factors for atherosclerosis, promoting diuresis and natriuresis, reducing uric acid, improving myocardial energy metabolism, maintaining sodium-calcium balance in cardiomyocytes, improving oxygen supply to the myocardium, having anti-inflammatory and anti fibrosis properties and reducing epicardial adipose tissue, etc. This article reviews the protective mechanism of SGLT2 inhibitors against cardiovascular diseases.